The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Did anyone attend the Investor Meet earlier today?
I could only attend for part of it, so would appreciate others thoughts.
I did pick up that the grass pollen allergen improvement of nearly 40% is a huge success and the regulatory bodies will often grant at as low as 20%.
Morning all, here's an update video from Manuel & team:
https://youtu.be/ZH5omT02aAU
Good morning. Webinar this Friday at 10am with CEO Manuel Llobet, CFO Nick Wykeman and Head of Business Innovation Alan Bullimore. Register on the link below:
https://us02web.zoom.us/webinar/register/WN_H6LkaFmdQkK2yP0FNQvqlg
The potential of an effective short-course peanut allergy vaccine represents a significant opportunity in the $8 billion worldwide food allergy market
The trial will include multiple cohorts beginning with healthy subjects, followed by peanut allergic patients who will undergo skin prick tests, and then peanut allergic patients who will receive subcutaneous injections. The topline data from the Phase I PROTECT trial in adult patients is expected in H1 2023, earlier than the originally intended data readout of Q4 2023.
https://www.londonstockexchange.com/news-article/AGY/fda-clearance-of-ind-application-for-vlp-peanut/15302034
I mean it's phase 1 trials there are years and years of trials ahead.
data/results to be released early next year..i wouldn't say years and years!
Phase 1, years and years to go...
Agreed! This year is going to be exciting!
Huge milestone achieved
Nothing has changed with the Company. Personally i see this as an opportunity to buy.
The company has lost a 3rd of its value in 2 months
Nothing to worry about here. The volumes have been small the last couple of days. Yesterday there were about 300,000 sells and today less than that. The company is still operating as usual, there has been no set back to the progress of nut allergy. There was a small amount of borrowing required but this is normal and the company is profitable so i don't really see anything wrong here. Markets have been down recently due to inflation and interest rates. some people may also just be taking some profits where they can.
Big decline in the SP recently..............any thoughts? I know the H1 results were somewhat underwhelming
That article in share magazine was a PAID advertising by Allergy Therapeutics.
Great article in this weeks share magazine covering Allergy Therapeutics, very positive, Pipeline should increase share price considerably next year. Sit tight worth the wait.
https://www.sharesmagazine.co.uk/magazine/2021-11-25-Shares
Looks like a good appointment preparing for commercialisation of forthcoming products. Anyone know anything further than the RNS?
theres a RNS released this morning not showing on LSE
It must just be the poor updating on this site. There’s a news piece that covers the positive trial results.
Surely now they must issue a statement (RNS) about the price movements - the volumes are too significant in relative terms for it to be just “market fluctuations”?
WTF has gone on here today with the SP? Another leak? Done a reversal and now powering on